Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk?
Open Access
- 3 May 2012
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 132 (2) , 417-426
Abstract
Given the strong link between use of unopposed estrogens and development of endometrial cancers, estrogens are usually prescribed with a progestin, particularly for women with intact uteri. Some studies suggest that sequential use of progestins may increase risk; however, the moderating effects of usage patterns or patient characteristics, including body mass index (BMI), are unknown. We evaluated menopausal hormone use and incident endometrial cancer (n = 885) in 68,419 postmenopausal women with intact uteri enrolled in the National Institutes of Health‐American Association of Retired Persons Diet and Health study. Participants completed a risk factor questionnaire in 1996–1997 and were followed up through 2006. Hazard rate ratios (RRs) and 95% confidence intervals (CIs) were estimated using Cox regression. Among 19,131 women reporting exclusive estrogen plus progestin use, 176 developed endometrial cancer (RR = 0.88; 95% CI = 0.74–1.06). Long‐duration (≥10 years) sequential (25 days progestin per month) estrogen plus progestin use was associated with a decreased risk (RR = 0.64; 95% CI = 0.49–0.83). Increased risk for sequential estrogen plus progestin was seen only among thin‐to‐normal weight women (BMI < 25 kg/m2; RR = 2.53). Our findings support that specific categories of estrogen plus progestin use increases endometrial cancer risk, specifically long durations of sequential progestins, whereas decreased endometrial cancer risk was observed for users of short‐duration continuous progestins. Risks were highest among thin‐to‐normal weight women, presumably reflecting their lower endogenous estrogen levels, suggesting that menopausal hormones and obesity increase endometrial cancer through common etiologic pathways.Keywords
This publication has 34 references indexed in Scilit:
- Long-term use of continuous-combined estrogen-progestin hormone therapy and risk of endometrial cancerCancer Causes & Control, 2011
- Association of Serum Sex Steroid Hormone Hemodilution and Body Mass Index Among Healthy Postmenopausal WomenAnnals of Epidemiology, 2011
- Body size and the risk of endometrial cancer by hormone therapy use in postmenopausal women in the California Teachers Study cohortCancer Causes & Control, 2010
- Long-term Postmenopausal Hormone Therapy and Endometrial CancerCancer Epidemiology, Biomarkers & Prevention, 2010
- Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses' Health Study cohort 1976–2004International Journal of Cancer, 2009
- Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studiesThe Lancet, 2008
- Anthropometric factors and risk of endometrial cancer: the European prospective investigation into cancer and nutritionCancer Causes & Control, 2007
- Effects of Conjugated Equine Estrogen in Postmenopausal Women With HysterectomyJAMA, 2004
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Design and Serendipity in Establishing a Large Cohort with Wide Dietary Intake DistributionsAmerican Journal of Epidemiology, 2001